Navigating Severe, Refractory Symptoms in a 50-Year-Old Patient with Systemic Mastocytosis

In this episode, ‘Navigating Severe, Refractory Symptoms in a 50-Year-Old Patient with Systemic Mastocytosis’ the expert dermatologist explores the following questions:

1. What are your impressions of this case? How would you classify SM in this patient, and what features suggest severe indolent disease vs progression to advanced SM?
2. In patients with a prolonged history of cutaneous and systemic symptoms, what factors make SM particularly challenging to diagnose and treat in dermatology practice?
3. How do you address the psychological impact of SM, particularly when a patient reports significant impact on quality of life?
4. How should dermatologists coordinate multidisciplinary care for a patient with SM who has significant cutaneous, gastrointestinal, and psychosocial manifestations?
5. What would prompt you to escalate from symptom-control therapy to targeted therapy in this patient?
6. How does avapritinib differ mechanistically from the previous SM therapies this patient has tried?
7. What has your experience been using avapritinib in SM? How does your experience using avapritinib compare to the long-term efficacy and safety data from the PIONEER trial?
8. How do you monitor treatment response and safety once initiating targeted therapy in SM?
9. What is the importance of adherence to targeted therapy in SM once initial symptom relief is achieved and what are some practical strategies for supporting adherence?

Dr. Madigan presents the case of a 50-year-old woman with refractory indolent systemic mastocytosis whose severe gastrointestinal and cutaneous symptoms persisted despite a high medication burden of antihistamines, cromolyn sodium, and oral steroids. Because the patient's quality of life was "destroyed" by daily flushing and diarrhea, Dr. Madigan escalated care to avapritinib, a selective KIT D816V tyrosine kinase inhibitor that targets the underlying driver of the disease. She explains that this targeted therapy provides significant and sustained improvements in objective metrics, such as serum tryptase and bone marrow mast cell density, while also visibly reducing the surface area and pigmentation of fixed skin lesions. To ensure safety, she emphasizes monitoring for periorbital edema and maintaining a platelet count above 50, noting that at the lower doses used for indolent disease, the treatment is generally well tolerated with very low discontinuation rates.

The next episode in this series, "Emerging Therapies and Expert Insights in Systemic Mastocytosis," features Dr. Madigan concluding by highlighting the promising clinical trial data for second-generation KIT inhibitors and summarizing essential practice pearls, such as the fact that over 90% of adults with fixed skin lesions meet the criteria for systemic disease. She stresses that clinicians must remain vigilant even when tryptase levels are below 20, as underestimating systemic involvement can lead to catastrophic consequences like fragility fractures or severe anaphylaxis.